A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling

PLoS ONE

Volumn 3, Issue 3, 2008, Pages

  Rosado, Aranzazú ^a,b   Zanella, Fabian ^a   Garcia, Beatriz ^a   Carnero, Amancio ^a   Link, Wolfgang ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYAN FLUORESCENT PROTEIN; INTERLEUKIN 3; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; STAT5 PROTEIN; YELLOW FLUORESCENT PROTEIN; FLUORESCENT DYE; PRIMER DNA; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; BIOENGINEERING; CANCER CHEMOTHERAPY; CELL GROWTH; CELL LINE; CELL SURVIVAL; COCULTURE; COISOGENIC STRAIN; CONTROLLED STUDY; DRUG SCREENING; FLUORESCENCE; IMAGING; LYMPHOBLAST; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCREENING; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NUCLEOTIDE SEQUENCE;

ANIMALS; BASE SEQUENCE; COCULTURE TECHNIQUES; DNA PRIMERS; FLUORESCENCE; FLUORESCENT DYES; INTERLEUKIN-3; MICE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 46649114168     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001823     Document Type: Article

References (23)

1. Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960-1964.
2. Balis FM (2002) Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst 94: 78-79.
3. Gibbs JB (2000) Mechanism-based target identification and drug discovery in cancer research. Science 287: 1969-1973.
4. Palacios R, Steinmetz M (1985) II-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41: 727-734.
5. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF (1999) Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 98: 181-191.
6. Sato N, Sakamaki K, Terada N, Arai K, Miyajima A (1993) Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. Embo J 12: 4181-4189.
7. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke TF (1997) Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci U S A 94: 11345-11350.
8. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760.
9. Hoover RR, Gerlach MJ, Koh EY, Daley GQ (2001) Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 20: 5826-5835.
10. Leverrier Y, Thomas J, Mathieu AL, Low W, Blanquier B, et al. (1999) Role of PI3-kinase in Bcl-X induction and apoptosis inhibition mediated by IL-3 or IGF-1 in Baf-3 cells. Cell Death Differ 6: 290-296.
11. Onishi M, Nosaka T, Misawa K, Mai ALF, Gonnan D, et al. (1998) Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Molecular and Cellular Biology 18: 3871-3879.
12. Burgering BM, Coffer PJ (1995) Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599-602.
13. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, et al. (1999) STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. Embo J 18: 4754-4765.
14. Chan TO, Rittenhouse SE, Tsichlis PN (1999) AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68: 965-1014.
15. Zanella F, Rosado A, Blanco F, Henderson BR, Carnero A, et al. (2007) An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. Assay Drug Dev Technol 5: 333-341.
16. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, et al. (2003) Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 375: 255-262.
17. Thimmaiah KN, Easton JB, Germain GS, Morton CL, Kamath S, et al. (2005) Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem 280: 31924-31935.
18. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW (2001) Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 19: 940-945.
19. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689.
20. Plas DR, Thompson CB (2003) Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 278: 12361-12366.
21. Carnero A, Hudson JD, Hannon GJ, Beach DH (2000) Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model. Nucleic Acids Res 28: 2234-2241.
22. Link W, Rosado A, Fominaya J, Thomas JE, Carnero A (2005) Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem 95: 979-989.
23. Zhang JH, Chung TDY, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening 4: 67-73.